UK pharma giant GlaxoSmithKline (LSE: GSK) has published promising data from a long-term analysis of lupus treatment Benlysta (belimumab).
The analysis showed patients with moderate-to-severe systemic lupus erythematosus (SLE) treated with Benlysta plus standard of care (SoC) over five years experienced low rates of organ damage progression, regardless of their baseline level of damage.
Patients with SLE are at risk of irreversible organ damage which will accrue over time and is associated with increased risk of death.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze